---
title: "BREAKINGVIEWS-DSM’s China de-risking plan hinges on booster shot"
description: "DSM-Firmenich plans to separate its animal nutrition business in 2025 to improve profitability. The unit has been affected by Chinese competitors driving down prices. The company aims to achieve a hig"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/108004216.md"
published_at: "2024-02-15T13:30:37.000Z"
---

# BREAKINGVIEWS-DSM’s China de-risking plan hinges on booster shot

> DSM-Firmenich plans to separate its animal nutrition business in 2025 to improve profitability. The unit has been affected by Chinese competitors driving down prices. The company aims to achieve a higher valuation by boosting EBITDA and increasing vitamin prices. CEO Dimitri de Vreeze is implementing a cost-cutting program to reach these goals. However, a decent valuation for the underperforming business may be challenging.

(The author is a Reuters Breakingviews columnist. The opinions expressed are her own.)

By Karen Kwok

LONDON, Feb 15 (Reuters Breakingviews) - DSM-Firmenich’s (DSFIR.AS) plan to break off its animal supplements business hinges on it receiving a much-needed booster shot. On Thursday, shares in the 28 billion euro Dutch chemicals group jumped 14% after it said it would separate its animal nutrition business. That’s logical given the unit has suffered from Chinese competitors driving down prices. But to get a decent price and justify investor enthusiasm, it will have to revive the business’s fortunes.

The market that provides vitamins for cattle is looking fallow. About 75% of global animal supplements come from China, which is enduring a prolonged economic slowdown. That has led to a surge in exports from the People’s Republic, which has depressed prices globally. Lower prices hit DSM hard in the past year and forced the Netherlands-listed company to close down plants to reduce costs. EBITDA generated in the animal nutrition and health unit, which makes animal vitamins, dropped 76% in 2023 to 128 million euros.

This weakness explains DSM’s decision to separate the animal nutrition unit in 2025. Selling or listing that business would drive up the group’s EBITDA margin to 18%, instead of the 14% DSM generated in 2023. Greater profitability could also help the remaining DSM businesses trade on a multiple closer to fragrance rival Givaudan (GIVN.S) . DSM is currently trading at 16 times its expected EBITDA for 2024, per Visible Alpha data, versus Givaudan’s 24 times.

Still, getting a decent valuation for an underperforming business will not be easy. DSM could sell the business to a private equity firm or a strategic buyer but it will have to boost its EBITDA. CEO Dimitri de Vreeze is banking on the success of a cost-cutting programme. Slashing overheads like closing down production plants could possibly bring the division’s EBITDA closer to 300 million euros by 2025 using UBS analysts’ estimate. If de Vreeze pulls it off, on the roughly 6 times EBITDA multiple as a mix of BASF (BASFn.DE) , Archer-Daniels-Midland (ADM.N) and China’s Zhejiang Nhu (002001.SZ) , the division could be worth 1.8 billion euros.

But de Vreeze needs vitamin prices to increase too. Thursday’s 14% share bump added some 3.2 billion euros to the Dutch company’s market value. Unless DSM proposes to unlock more value by further breakups of its business, the animal nutrition business’s EBITDA would have to reach 500 million euros to justify DSM’s new valuation of 30 billion euros including net debt. De Vreeze has the right idea, but his transition is still in its infancy.

Follow @karenkkwok on X

### CONTEXT NEWS

Dutch-listed chemicals company DSM-Firmenich on Feb. 15 said it plans to separate its animal nutrition and health business in 2025.

The company, born out of a merger of Netherlands-based DSM and Swiss company Firmenich in May 2022, is also reviewing which parts of the animal nutrition and health division should be part of the separation. Revenue in the animal nutrition and health business fell 15% to 3.2 billion euros in 2023. This division accounted for a quarter of DSM-Firmenich’s 12.3 billion euros of total sales in 2023.

The company remains confident in achieving annual savings of around 200 million euros by the end of 2024 through a restructuring programme announced in June 2023.

Shares of DSM-Firmenich were up 11.6% by 0915 GMT on Feb. 15.

(Editing by Aimee Donnellan, Streisand Neto and Oliver Taslic)

### Related Stocks

- [ADM.US - Archer-Daniels-Midland](https://longbridge.com/en/quote/ADM.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 阿彻丹尼尔斯米德兰｜10-K：2025 财年营收 803 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/276167327.md) |
| 由于中国需求疲软以及巴西供应充足，大豆价格下滑 | 大豆期货价格下跌至每蒲式耳 11.42 美元，连续第二个交易日出现亏损，原因是作为最大进口国的中国需求疲软，且在假期期间未进行交易。此前，由于美国总统特朗普关于中国可能增加美国大豆采购的言论，价格曾飙升至两个月来的高点。然而，缺乏确认的交易 | [Link](https://longbridge.com/en/news/276095672.md) |
| 阿彻丹尼尔斯米德兰｜8-K：2025 财年营收 803 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/274643525.md) |
| CBOT 大豆价格上涨，但对中国需求的疑虑仍然存在 | 芝加哥商品交易所的大豆期货小幅上涨，因市场对中国采购的期望，尽管由于农历新年假期对需求的担忧依然存在。三月份的大豆收于每蒲式耳 11.34 美元，而豆粕和豆油的表现则参差不齐。随着巴西大豆收割的推进，市场保持谨慎，对中国额外采购的怀疑可能限 | [Link](https://longbridge.com/en/news/276161248.md) |
| 由于中国需求前景，大豆有望连续第三周上涨 | 芝加哥大豆期货保持稳定，因预计中国对美国货物的需求而达到三个月来的最高点。本周大豆价格上涨约 2%，连续三周上涨。玉米价格下降超过 1%，而小麦价格上涨超过 3%。预计美国农民在 2026 年将种植更多的大豆和更少的玉米，两个作物的收成预计 | [Link](https://longbridge.com/en/news/276400900.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.